Gracia-Fleta F, Medrano-Martínez V, Castaño-Pérez M D, Hernández-Lorido R, Mañes R
Servicio de Neurología, Hospital General Universitario de Alicante, Alicante, España.
Rev Neurol. 2001;32(1):45-9.
To evaluate monotherapy treatment with the anticonvulsant drug gabapentin, its efficacy and tolerability when used in patients with partial and secondary generalized partial epileptic seizures of recent onset who had not received treatment or who, in spite of treatment with other antiepileptic drugs failed to attain control over their seizures.
We made an open prospective study of 50 patients diagnosed as having partial and secondarily generalized partial epileptic seizures. The patients were given treatment at their first visit and them regularly followed up for two years. Treatment was given progressively until a maintenance dose of 1.200 mg/day was reached, and the dose them adjusted individually.
We included 50 patients in the study; 78% were treated with gabapentin. Ten percent stopped this treatment because it was ineffective. All the patients who continued their treatment with gabapentin had their seizures reduced by over 50%. This reduction in the number of seizures is statistically significant (p < 0.05) for patients with partial and secondarily generalized partial seizures. Twelve percent of the group of patients stopped their treatment because of side-effects.
When the results of our study are evaluated and compared with those published in the literature, it may be seen that gabapentin is a safe, effective drug which is well tolerated when used as monotherapy for the treatment of patients with partial seizures.
评估抗惊厥药物加巴喷丁单药治疗的效果，以及其用于近期发作的部分性和继发性全身性部分性癫痫发作患者（未接受过治疗或虽接受其他抗癫痫药物治疗但未能控制癫痫发作）时的疗效和耐受性。
我们对50例被诊断为部分性和继发性全身性部分性癫痫发作的患者进行了开放性前瞻性研究。患者在首次就诊时接受治疗，并定期随访两年。治疗逐步进行，直至达到1200毫克/天的维持剂量，然后根据个体情况调整剂量。
我们纳入了50例患者进行研究；78%的患者接受了加巴喷丁治疗。10%的患者因治疗无效而停止治疗。所有继续使用加巴喷丁治疗的患者癫痫发作次数减少了50%以上。对于部分性和继发性全身性部分性癫痫发作患者，癫痫发作次数的减少具有统计学意义（p < 0.05）。12%的患者因副作用而停止治疗。
当对我们的研究结果进行评估并与文献中发表的结果进行比较时，可以发现加巴喷丁是一种安全、有效的药物，作为单药治疗部分性癫痫发作患者时耐受性良好。
